Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J/CHIRON REGRANEX LAUNCH TO FEATURE DIABETIC FOOT ULCER EDUCATIONAL PROGRAM; LIMITED EFFICACY OUTWEIGHED BY SERIOUSNESS OF DISEASE -- FDA ADVISORY CMTE.

Executive Summary

McNeil is planning an educational program for physicians emphasizing state-of-the art wound treatment techniques in conjunction with the launch of the recombinant human platelet-derived growth factor product Regranex.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS030556

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel